Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q3 2018 · 10-Q
Revenue$78.00K$78.00K+110.8% vs Q3 2017 Net Income-$3.96M-$3.96MN/M vs Q3 2017 EPS Diluted-$0.35-$0.35N/M vs Q3 2017 Operating Income-$3,493,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,935,000N/M Margins · derivedOperating margin-4478.2%+6159.6 pt vs Q3 2017
Net margin-5079.5%+5496.2 pt vs Q3 2017
ended Mar 31, 2018 · filed May 11, 2018 · 41 d after period end